Terms: = Breast cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Clinical Outcome
14 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer.
Fong LWR; Lee J; Lin HK; Ueno NT; Zhang S
Sci Rep; 2022 Feb; 12(1):2478. PubMed ID: 35169199
[TBL] [Abstract] [Full Text] [Related]
3. Increased Expression of LIPC Is Associated with Aggressive Phenotype of Borrmann Type 4 Gastric cancer.
Huang JY; Zhang WL; Xing YN; Hou WB; Yin SC; Wang ZN; Tan YE; Xu YY; Zhu Z; Xu HM
J Gastrointest Surg; 2021 Apr; 25(4):900-910. PubMed ID: 32157605
[TBL] [Abstract] [Full Text] [Related]
4. PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA.
Tan L; Mai D; Zhang B; Jiang X; Zhang J; Bai R; Ye Y; Li M; Pan L; Su J; Zheng Y; Liu Z; Zuo Z; Zhao Q; Li X; Huang X; Yang J; Tan W; Zheng J; Lin D
Mol Cancer; 2019 Jan; 18(1):9. PubMed ID: 30636640
[TBL] [Abstract] [Full Text] [Related]
5.
Flanagan DJ; Barker N; Costanzo NSD; Mason EA; Gurney A; Meniel VS; Koushyar S; Austin CR; Ernst M; Pearson HB; Boussioutas A; Clevers H; Phesse TJ; Vincan E
Cancer Res; 2019 Mar; 79(5):970-981. PubMed ID: 30622113
[TBL] [Abstract] [Full Text] [Related]
6. EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth.
Perurena N; Zandueta C; MartÃnez-Canarias S; Moreno H; Vicent S; Almeida AS; Guruceaga E; Gomis RR; Santisteban M; Egeblad M; Hermida J; Lecanda F
J Hematol Oncol; 2017 Jan; 10(1):23. PubMed ID: 28103946
[TBL] [Abstract] [Full Text] [Related]
7. Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients.
Li Z; Heng J; Yan J; Guo X; Tang L; Chen M; Peng L; Wu Y; Wang S; Xiao Z; Deng Z; Dai L; Wang J
Breast Cancer Res Treat; 2016 Nov; 160(2):371-383. PubMed ID: 27722841
[TBL] [Abstract] [Full Text] [Related]
8. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
Lee SY; Im SA; Park YH; Woo SY; Kim S; Choi MK; Chang W; Ahn JS; Im YH
Eur J Cancer; 2014 Mar; 50(4):698-705. PubMed ID: 24361227
[TBL] [Abstract] [Full Text] [Related]
9. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
[TBL] [Abstract] [Full Text] [Related]
10. Should young age be a contra-indication to breast conservation treatment in Chinese women? Twelve-year experience from a public cancer centre in Hong Kong.
Yau TK; Choi CW; Sze H; Soong IS; Lee AW
Hong Kong Med J; 2009 Apr; 15(2):94-9. PubMed ID: 19342734
[TBL] [Abstract] [Full Text] [Related]
11. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
Viale G; Rotmensz N; Maisonneuve P; Bottiglieri L; Montagna E; Luini A; Veronesi P; Intra M; Torrisi R; Cardillo A; Campagnoli E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2009 Jul; 116(2):317-28. PubMed ID: 18839307
[TBL] [Abstract] [Full Text] [Related]
12. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer.
Vlastos G; Rubio IT; Mirza NQ; Newman LA; Aurora R; Alderfer J; Buzdar AU; Singletary SE
Ann Surg Oncol; 2000 Sep; 7(8):581-7. PubMed ID: 11005556
[TBL] [Abstract] [Full Text] [Related]
13. Insulin receptor expression and clinical outcome in node-negative breast cancer.
Mathieu MC; Clark GM; Allred DC; Goldfine ID; Vigneri R
Proc Assoc Am Physicians; 1997 Nov; 109(6):565-71. PubMed ID: 9394418
[TBL] [Abstract] [Full Text] [Related]
14. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
[TBL] [Abstract] [Full Text] [Related]
